Uehara Takashi, Yoshida Hiroshi, Kato Tomoyasu
Department of Gynecology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.
Department of Diagnostic Pathology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.
Gynecol Oncol Rep. 2020 Dec 28;35:100692. doi: 10.1016/j.gore.2020.100692. eCollection 2021 Feb.
•A 56-year-old woman developed two seromucinous borderline tumors 26 years apart.•The second cyst was diagnosed as a seromucinous borderline tumor associated with pelvic endometriosis.•The first ovarian cancer was re-diagnosed as an ovarian seromucinous borderline tumor after a pathological slide review.•Seromucinous borderline tumors can re-occur several years after post-treatment estrogen replacement therapy.•Post-treatment estrogen replacement therapy for seromucinous borderline tumors should be provided carefully.
•一名56岁女性在26年间先后出现了两个浆液性黏液性交界性肿瘤。
•第二个囊肿被诊断为与盆腔子宫内膜异位症相关的浆液性黏液性交界性肿瘤。
•经病理切片复查后，首次诊断的卵巢癌被重新诊断为卵巢浆液性黏液性交界性肿瘤。
•浆液性黏液性交界性肿瘤可在治疗后雌激素替代治疗数年之后复发。
•对于浆液性黏液性交界性肿瘤，治疗后的雌激素替代治疗应谨慎进行。
